Tokyo, Dec. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060079) titled 'Dual ultrasound screening by heart brain team to improve the detection of PFO in cryptogenic stroke patients' on Dec. 14.

Study Type: Observational

Primary Sponsor: Institute - Showa Medical University

Condition: Condition - Cryptogenic stroke Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The aim of this study is to evaluate whether dual screening combining transthoracic echocardiography (TTE) and transcranial Doppler (TCD) performed by a multidisciplinary heart brain team can improve the diagnostic accuracy for detecting patent foramen ovale (PFO) in patients with cryptogenic stroke, compared with either modality alone. In particular, the study seeks to clarify the incremental value of combining both modalities in reducing missed diagnoses and to establish an optimal collaborative screening strategy for clinical practice. Basic objectives2 - Efficacy

Eligibility: Age-lower limit - 10 years-old < Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients diagnosed by stroke specialists as having ischemic stroke or transient ischemic attack (TIA) suspected to be cryptogenic or possibly related to patent foramen ovale (PFO). Patients who underwent both transthoracic echocardiography (TTE) and transcranial Doppler (TCD) bubble tests as part of the diagnostic screening for PFO. Patients who also underwent transesophageal echocardiography (TEE) for definitive confirmation of PFO. Age over than 10 years. Sufficient clinical and echocardiographic data available for retrospective analysis. Key exclusion criteria - Patients who did not undergo either transthoracic echocardiography (TTE) or transcranial Doppler (TCD) bubble test. Patients in whom transesophageal echocardiography (TEE) was not performed or yielded inadequate imaging for confirmation of PFO. Cases with technically inadequate TTE or TCD images, or insufficient visualization for bubble counting. Patients with other known causes of right-to-left shunt (e.g., pulmonary arteriovenous malformation, atrial septal defect) unrelated to PFO. Patients with severe comorbid conditions (e.g., advanced heart failure, malignancy) in whom standard screening was not completed. Incomplete clinical or echocardiographic data precluding accurate analysis. Target Size - 400

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2025 Year 11 Month 27 Day Date of IRB - 2025 Year 11 Month 27 Day Anticipated trial start date - 2025 Year 11 Month 27 Day Last follow-up date - 2026 Year 11 Month 27 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068242

Disclaimer: Curated by HT Syndication.